Upfront payment to Pfizer totaled USD 12 million, with another USD 15 million due on the first anniversary.
Pfizer paid USD 2 million in development funding restricted to the program; potential milestones exceed USD 1 billion with low double-digit royalties.
Pfizer can opt to fund development from the first pivotal trial under a separate agreement; Medicus retains control of development and commercialization.
Pfizer and Medicus Pharma enter CD228V co-development deal
Medicus Pharma entered a co-development and license deal with Pfizer for PF-08046031 (CD228V), an early-stage antibody-drug conjugate.
Pfizer granted an exclusive worldwide license to develop, manufacture and commercialize CD228V, subject to retained rights; Pfizer keeps patent ownership.
PFE•
